Clinical assessment of azapropazone in rheumatoid arthritis.
Azapropazone was investigated in a 2-week double-blind clinical out-patient trial against placebo in 23 patients with definite rheumatoid arthritis. The drug was given at a dose of 1200 mg. per day before food. At this dose level the drug was shown to have an antirheumatic effect in terms of pain relief, articular tenderness and duration of morning stiffness.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001032:Apazone / Q000008:administration & dosage / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D010919:Placebos; D012075:Remission, Spontaneous; D014227:Triazines / Q000627:therapeutic use*
D010919:Placebos; D014227:Triazines; D001032:Apazone